NO324215B1 - Anvendelse av levobupivakain for fremstilling av et medikament - Google Patents
Anvendelse av levobupivakain for fremstilling av et medikament Download PDFInfo
- Publication number
- NO324215B1 NO324215B1 NO19994259A NO994259A NO324215B1 NO 324215 B1 NO324215 B1 NO 324215B1 NO 19994259 A NO19994259 A NO 19994259A NO 994259 A NO994259 A NO 994259A NO 324215 B1 NO324215 B1 NO 324215B1
- Authority
- NO
- Norway
- Prior art keywords
- levobupivacaine
- bupivacaine
- doses
- drug
- absence
- Prior art date
Links
- LEBVLXFERQHONN-INIZCTEOSA-N levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 title claims abstract description 47
- 229960004288 levobupivacaine Drugs 0.000 title claims abstract description 46
- 239000003814 drug Substances 0.000 title claims description 17
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 229940079593 drug Drugs 0.000 title description 15
- 238000001356 surgical procedure Methods 0.000 claims abstract description 11
- 230000036592 analgesia Effects 0.000 claims abstract description 8
- 206010002091 Anaesthesia Diseases 0.000 claims abstract description 4
- 230000037005 anaesthesia Effects 0.000 claims abstract description 4
- 238000001802 infusion Methods 0.000 claims description 7
- 210000003141 lower extremity Anatomy 0.000 claims description 2
- 210000001364 upper extremity Anatomy 0.000 claims description 2
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 238000001949 anaesthesia Methods 0.000 abstract 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 21
- 229960003150 bupivacaine Drugs 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 9
- 210000003169 central nervous system Anatomy 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 230000003444 anaesthetic effect Effects 0.000 description 3
- LEBVLXFERQHONN-MRXNPFEDSA-N dextrobupivacaine Chemical compound CCCCN1CCCC[C@@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-MRXNPFEDSA-N 0.000 description 3
- 230000001738 genotoxic effect Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 231100000457 cardiotoxic Toxicity 0.000 description 2
- 230000001451 cardiotoxic effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 231100000025 genetic toxicology Toxicity 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229940127558 rescue medication Drugs 0.000 description 2
- 229960003962 trifluridine Drugs 0.000 description 2
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 2
- YHQDZJICGQWFHK-UHFFFAOYSA-N 4-nitroquinoline N-oxide Chemical compound C1=CC=C2C([N+](=O)[O-])=CC=[N+]([O-])C2=C1 YHQDZJICGQWFHK-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004903 cardiac system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229940005494 general anesthetics Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 231100000628 reference dose Toxicity 0.000 description 1
- 238000002694 regional anesthesia Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9704351.7A GB9704351D0 (en) | 1997-03-03 | 1997-03-03 | Levobupivacaine and its use |
| PCT/GB1998/000664 WO1998038999A1 (en) | 1997-03-03 | 1998-03-03 | The use of levobupivacaine in paediatric surgery |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO994259D0 NO994259D0 (no) | 1999-09-02 |
| NO994259L NO994259L (no) | 1999-11-02 |
| NO324215B1 true NO324215B1 (no) | 2007-09-10 |
Family
ID=10808602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19994259A NO324215B1 (no) | 1997-03-03 | 1999-09-02 | Anvendelse av levobupivakain for fremstilling av et medikament |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5910502A (enExample) |
| EP (1) | EP0981348B1 (enExample) |
| JP (1) | JP2001513814A (enExample) |
| KR (1) | KR100535554B1 (enExample) |
| CN (1) | CN1107504C (enExample) |
| AT (1) | ATE240731T1 (enExample) |
| AU (1) | AU719483B2 (enExample) |
| BR (1) | BR9808302A (enExample) |
| CA (1) | CA2279498C (enExample) |
| DE (1) | DE69814852T2 (enExample) |
| DK (1) | DK0981348T3 (enExample) |
| ES (1) | ES2199424T3 (enExample) |
| GB (1) | GB9704351D0 (enExample) |
| HU (1) | HU224227B1 (enExample) |
| IL (1) | IL131086A0 (enExample) |
| NO (1) | NO324215B1 (enExample) |
| PL (1) | PL190896B1 (enExample) |
| PT (1) | PT981348E (enExample) |
| WO (1) | WO1998038999A1 (enExample) |
| ZA (1) | ZA981780B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1030652B1 (en) | 1997-11-14 | 2012-04-25 | Pacira Pharmaceuticals, Inc. | Production of multivesicular liposomes |
| IL140899A0 (en) | 1998-07-17 | 2002-02-10 | Skyepharma Inc | Lipid/polymer containing pharmaceutical compositions and processes for the preparation thereof |
| IL158819A0 (en) * | 2001-05-31 | 2004-05-12 | Skyepharma Inc | Encapsulation of nanosuspensions in liposomes and microspheres |
| JP2005519873A (ja) * | 2001-11-14 | 2005-07-07 | アルザ・コーポレーション | カテーテル注入可能なデポー組成物およびそれらの使用 |
| CA2466632C (en) * | 2001-11-14 | 2014-02-11 | Alza Corporation | Injectable depot compositions and uses thereof |
| US20070196415A1 (en) * | 2002-11-14 | 2007-08-23 | Guohua Chen | Depot compositions with multiple drug release rate controls and uses thereof |
| US20040001889A1 (en) * | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
| EP2030611A1 (en) * | 2002-07-31 | 2009-03-04 | Alza Corporation | Injectable multimodal polymer depot compositions and uses thereof |
| IL166418A0 (en) * | 2002-07-31 | 2006-01-15 | Alza Corp | Injectable depot compositions and uses thereof |
| US20060142234A1 (en) * | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
| CN105764491A (zh) | 2013-12-09 | 2016-07-13 | 度瑞公司 | 药物活性剂复合物、聚合物复合物，以及包括其的组合物和方法 |
| KR20220140711A (ko) | 2020-01-13 | 2022-10-18 | 듀렉트 코퍼레이션 | 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법 |
| EP4277702A1 (en) | 2021-01-12 | 2023-11-22 | Durect Corporation | Sustained release drug delivery systems and related methods |
| US12151024B2 (en) | 2021-01-22 | 2024-11-26 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| US11357727B1 (en) | 2021-01-22 | 2022-06-14 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| US11278494B1 (en) | 2021-01-22 | 2022-03-22 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| US11033495B1 (en) | 2021-01-22 | 2021-06-15 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| EP4415713A4 (en) | 2021-10-14 | 2025-08-06 | Pacira Pharmaceuticals Inc | MULTIVESICULAR LIPOSOME FORMULATIONS OF BUPIVACAINE AND THEIR USES |
| US12280149B1 (en) | 2024-05-20 | 2025-04-22 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| US12251472B1 (en) | 2024-05-20 | 2025-03-18 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| US12156940B1 (en) | 2024-05-20 | 2024-12-03 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0151110B1 (en) * | 1983-08-01 | 1989-03-01 | Astra Läkemedel Aktiebolag | L-n-n-propylpipecolic acid-2,6-xylidide and method for preparing the same |
| ES2170179T3 (es) * | 1993-10-13 | 2002-08-01 | Darwin Discovery Ltd | Agente analgesico y su utilizacion. |
| EP0821588B1 (en) * | 1995-04-13 | 2003-06-18 | Darwin Discovery Limited | Levobupivacaine and its use as an anaesthetic in pregnant women |
-
1997
- 1997-03-03 GB GBGB9704351.7A patent/GB9704351D0/en active Pending
-
1998
- 1998-03-03 HU HU0000963A patent/HU224227B1/hu active IP Right Grant
- 1998-03-03 PL PL335563A patent/PL190896B1/pl unknown
- 1998-03-03 AT AT98908230T patent/ATE240731T1/de active
- 1998-03-03 CN CN98802993A patent/CN1107504C/zh not_active Expired - Lifetime
- 1998-03-03 AU AU66310/98A patent/AU719483B2/en not_active Expired
- 1998-03-03 JP JP53827698A patent/JP2001513814A/ja active Pending
- 1998-03-03 EP EP98908230A patent/EP0981348B1/en not_active Expired - Lifetime
- 1998-03-03 ZA ZA981780A patent/ZA981780B/xx unknown
- 1998-03-03 DK DK98908230T patent/DK0981348T3/da active
- 1998-03-03 PT PT98908230T patent/PT981348E/pt unknown
- 1998-03-03 BR BR9808302-3A patent/BR9808302A/pt not_active Application Discontinuation
- 1998-03-03 DE DE69814852T patent/DE69814852T2/de not_active Expired - Lifetime
- 1998-03-03 WO PCT/GB1998/000664 patent/WO1998038999A1/en not_active Ceased
- 1998-03-03 IL IL13108698A patent/IL131086A0/xx not_active IP Right Cessation
- 1998-03-03 ES ES98908230T patent/ES2199424T3/es not_active Expired - Lifetime
- 1998-03-03 KR KR10-1999-7007973A patent/KR100535554B1/ko not_active Expired - Lifetime
- 1998-03-03 CA CA002279498A patent/CA2279498C/en not_active Expired - Lifetime
- 1998-03-03 US US09/034,070 patent/US5910502A/en not_active Expired - Lifetime
-
1999
- 1999-09-02 NO NO19994259A patent/NO324215B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| PL335563A1 (en) | 2000-05-08 |
| DK0981348T3 (da) | 2003-09-15 |
| KR100535554B1 (ko) | 2005-12-08 |
| US5910502A (en) | 1999-06-08 |
| CN1249683A (zh) | 2000-04-05 |
| CN1107504C (zh) | 2003-05-07 |
| EP0981348B1 (en) | 2003-05-21 |
| CA2279498C (en) | 2009-05-26 |
| AU719483B2 (en) | 2000-05-11 |
| NO994259D0 (no) | 1999-09-02 |
| HU224227B1 (hu) | 2005-06-28 |
| HUP0000963A3 (en) | 2000-10-30 |
| AU6631098A (en) | 1998-09-22 |
| DE69814852T2 (de) | 2004-01-22 |
| PL190896B1 (pl) | 2006-02-28 |
| BR9808302A (pt) | 2000-05-16 |
| JP2001513814A (ja) | 2001-09-04 |
| WO1998038999A1 (en) | 1998-09-11 |
| EP0981348A1 (en) | 2000-03-01 |
| GB9704351D0 (en) | 1997-04-23 |
| PT981348E (pt) | 2003-09-30 |
| DE69814852D1 (de) | 2003-06-26 |
| ZA981780B (en) | 1999-03-03 |
| CA2279498A1 (en) | 1998-09-11 |
| HUP0000963A2 (hu) | 2000-09-28 |
| HK1022649A1 (en) | 2000-08-18 |
| NO994259L (no) | 1999-11-02 |
| ATE240731T1 (de) | 2003-06-15 |
| ES2199424T3 (es) | 2004-02-16 |
| KR20000075894A (ko) | 2000-12-26 |
| IL131086A0 (en) | 2001-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO324215B1 (no) | Anvendelse av levobupivakain for fremstilling av et medikament | |
| Phillips-Howard et al. | The safety of antimalarial drugs in pregnancy | |
| Van den Berg et al. | The oculo‐emetic reflex: A rationalisation of postophthalmic anaesthesia vomiting | |
| Murdoch | Peribulbar versus retrobulbar anaesthesia | |
| US5849763A (en) | Use of levobupivacaine as an anesthetic agent | |
| KR100516676B1 (ko) | 안면 수술에서의 레보부피바카인의 용도 | |
| Boezaart et al. | A comparison of propofol and remifentanil for sedation and limitation of movement during periretrobulbar block | |
| Kallio et al. | Topical anesthesia with or without propofol sedation versus retrobulbar/peribulbar anesthesia for cataract extraction: prospective randomized trial | |
| Logan et al. | SINGLE-SHOT IV ANAESTHESIA FOR OUTPATIENT DENTAL SURGERY: Comparison of 2, 6 Di-isopropyl Phenol and Methohexitone | |
| US20040192699A1 (en) | Optic nerve protecting agents containing alpha1 receptor blocker as active ingredient | |
| JPH08507774A (ja) | 手術後の悪心および嘔吐の治療のためのグラニセトロンの使用 | |
| McCLANAHAN et al. | Ocular manifestations of chronic phenothiazine derivative administration | |
| SK280111B6 (sk) | Použitie ropivakaínu na výrobu farmaceutického pro | |
| Watson et al. | Effect of nebulized ipratropium bromide on intraocular pressures in children | |
| EP3701956B1 (en) | Prophylactic and/or therapeutic agent for dementia | |
| Harris et al. | The use of CI-581, a new parenteral anesthetic, in ophthalmic practice | |
| Kovac et al. | Effect of esmolol on hemodynamics and intraocular pressure response to succinylcholine and intubation following low-dose alfentanil premedication | |
| HK1022649B (en) | The use of levobupivacaine in paediatric surgery | |
| MXPA99008057A (en) | The use of levobupivacaine in paediatric surgery | |
| Lear et al. | Comparative studies of tranquilizers used in anesthesia | |
| WO1998038997A1 (en) | Use of levobupivacaine in combination with opiods or alfa2-agonists for providing anaesthesia or analgesia | |
| Salem et al. | The effects of atropine and glycopyrrolate on intra‐ocular pressure in anasthetised elderly patients | |
| Fathi et al. | Carticaine versus lidocaine for peribulbar anesthesia in cataract surgery | |
| Kinross-Wright | Succinylcholine in electroshock treatment | |
| Dornette et al. | Clinical and laboratory experience with ethyl vinyl ether. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |